Veterinary method of alleviating noise aversion
The invention relates to a method for alleviating noise aversion in animals, particularly dogs, comprising administering to a subject in need thereof an effective amount of dexmedetomidine, medetomidine or a pharmaceutically acceptable salt thereof as the active ingredient. The active ingredient is preferably administered oromucosally, e.g. in the form of an oromucosal gel.
1. A method for alleviating noise aversion in a dog without producing clinical sedation, comprising administering to the dog in need thereof a noise-aversion alleviating amount of dexmedetomidine or a pharmaceutically acceptable salt thereof that does not produce clinical sedation, wherein the amount of dexmedetomidine or a pharmaceutically acceptable salt thereof ranges from 100 μg/m 2 to 150 μg/m 2 , wherein dexmedetomidine or a pharmaceutically acceptable salt thereof is administered oromucosally in the form of a semisolid oromucosal gel.
2. The method according to claim 1 , wherein the semisolid oromucosal gel comprises, per weight of the composition, 0.001-0.2% (w/w) of dexmedetomidine or a pharmaceutically acceptable salt thereof; 1-40% (w/w) of a gelling agent; 0.2-10% (w/w) of a transmucosal penetration enhancer; 5-50% (w/w) of a water-miscible organic co-solvent; and 30-80% (w/w) of water.
3. The method according to claim 1 , wherein the plasma C max value of dexmedetomidine in the dog is from about 0.05 ng/ml to about 0.8 ng/ml.
4. The method according claim 1 , wherein the plasma C max value of dexmedetomidine in the dog is from about 0.15 ng/ml to about 0.6 ng/ml.
5. The method according claim 1 , wherein the plasma C max value of dexmedetomidine in the dog is from about 0.2 ng/ml to about 0.5 ng/ml.
6. The method according to claim 1 , wherein the dog retains its ability to stand up and walk without signs of ataxia.
7. The method according to claim 1 , wherein the dog suffers from noise phobia.